Uncovering Iran’s Methadone Crisis: Profits, Addiction, and the Silent Epidemic Threatening a Nation
Methadone abuse has emerged as a critical issue in Iran, driven by insufficient oversight and the profit motives of the pharmaceutical industry. This crisis has led to a disturbing rise in deaths, including among children, and has ensnared millions in the throes of addiction.
A notable concern is the alarming trend of doctors turning into methadone dealers. Dr. Mohammadreza Mohammadi, a child and adolescent psychiatrist, has highlighted that thousands of Iranian doctors have shifted their focus from medical care to the lucrative sales of methadone. According to him, over 9,000 doctors are now prescribing and selling methadone instead of providing essential services like psychotherapy and counseling. This shift is largely attributed to weak supervision of addiction treatment centers that has led to methadone entering the free market, perpetuating addiction rather than encouraging recovery.
“This trend perpetuates the cycle of addiction,” Mohammadi explained, noting that users frequently return to treatment camps without achieving lasting recovery, while public dissatisfaction continues to grow.
Iran’s Dominance in Methadone Production
Dr. Mohammadi reveals that Iran plays a significant role in methadone production, contributing to over half of the global supply. He states that while the world produces approximately 60 tons of methadone annually, Iran alone accounts for 30-35 tons. The immense profits generated from this trade have incentivized many doctors and pharmaceutical companies to abandon their professional responsibilities in pursuit of wealth.
Currently, Iran operates one of the largest methadone maintenance treatment networks globally, boasting over 7,000 clinics that dispense millions of doses each year. Although large pharmaceutical firms officially control production, illegal networks and smuggling have made methadone readily available outside clinical settings.
Key Pharmaceutical Players in Methadone Production
The methadone market in Iran is heavily influenced by several pharmaceutical giants. In 2023, the production was dominated by:
- Darou Pakhsh Pharmaceutical Company – 23.9%
- Faran Shimi Pharmaceutical – 21.1%
- Darou Pakhsh Raw Materials Production (Temad) – 16.4%
- Exir Pharmaceutical – 15.3%
- Mehr Darou – 8.8%
- Zagros Darou Parsian – 7.3%
- Darou Darman Pars – 4.4%
- Soha Pharmaceutical – 2.8%
Despite these official figures, experts confirm that a significant portion of methadone is diverted into the informal market through smuggling and other illicit activities.
Rising Death Toll from Methadone Abuse
Methadone abuse has become a leading cause of drug-related fatalities in Iran. Between 2020 and 2021, the provinces with the highest methadone-related death rates per million included:
- Kermanshah – 178.2 deaths
- Lorestan – 139 deaths
- Kohgiluyeh and Boyer-Ahmad – 119.4 deaths
Even more distressing, during the same period, there were reports of 21 infants under one year old and 81 children aged one to seven who died from methadone poisoning. In total, methadone and related compounds contributed to over 5,900 deaths out of approximately 11,336 drug-related fatalities nationwide.
In 2023, methadone poisoning was responsible for the largest share of drug deaths, with 2,584 victims. Experts are raising alarms about a hidden crisis as many addicts consume methadone outside of treatment centers, remaining uncounted in official statistics.
The Scale of Addiction in Iran
Official statistics from 2024 indicate that approximately 1.6 million people are currently in treatment at addiction centers. However, experts believe the actual number of addicts is far higher. Former deputy health minister Reza Malekzadeh has warned that nearly 10% of Iran’s population, or about 8 to 9 million people, uses opium, with provinces like Rafsanjan and Golestan showing the highest prevalence rates. This alarming statistic suggests a significant rise in drug dependency, particularly among the youth.
Reports indicate that 58% of identified addicts in Iran are under the age of 34, highlighting a concerning trend of declining average age of addiction onset. Economic challenges have also shifted drug preferences, with heroin and crystal meth becoming increasingly common as opium prices rise.
Contradictions in Statistics and Realities
Contradictory statistics complicate the understanding of the addiction crisis. The president of the Iran University of Medical Sciences estimates that there are 2.8 million active addicts. However, when considering family members affected by addiction, the total number may range from 10 to 12 million Iranians directly or indirectly impacted.
A nationwide survey of addiction therapists across all provinces indicates that the daily use of methadone syrup and pills has become a common practice among addicts, underscoring just how accessible the drug has become.
The Urgent Need for Action
The methadone crisis in Iran is not just a health issue but a profound societal problem reflective of failures in governance, health policy, and economic integrity. Weak regulation, pharmaceutical profiteering, and medical professionals incentivized to sell rather than heal have combined to create a deadly epidemic. With millions of Iranians ensnared in the cycle of addiction and thousands succumbing each year, many experts warn that the country faces one of its most pressing social and health crises.
